mRNA Day: TriLink, Maravai Look to RNA, Oligonucleotides, and San Diego for Growth | GEN – Genetic Engineering and Biotechnology News

A San Diego manufacturer of highly-modified nucleic acids and its parent company have concluded that development of RNA- and oligonucleotide-based therapeutics—as well as the region’s biopharma cluster—will both grow strongly enough in the near future to justify the companies’ recent $50-million investment in relocation and expansion within the city.

Read the full article here

Related Articles